With the latest data coming out of the COVID-19 remdesivir trials, not to mention considerable observational data, leading voices in the research community, such as Dr. Anthony Fauci, report an overall optimistic tone—but it’s not a knockout punch against the novel coronavirus.
Recent findings reported yesterday by Emory University reveal promising results from remdesivir: the drug does cut down on hospitalization duration for COVID-19 patients. However, the effect on mortality was statistically insignificant. But because of the benefits observed, the U.S. government plans on making the drug available as quickly as possible.
Call to Action: Read Kaiser Health News morning brief for more information.